Filtered By:
Drug: Fluoxetine

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 187 results found since Jan 2013.

Fluoxetine enhances Brain Derived Neurotropic Factor Serum Concentration and Cognition in Patients with Vascular Dementia.
Abstract Selective serotonin reuptake inhibitors (SSRIs) improve cognition in patients with stroke and increase the expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. However, the effects of SSRIs on cognition and BDNF level in vascular dementia (VaD) patients are largely unknown. We performed an open-label study to investigate the effects of fluoxetine, a selective serotonin reuptake inhibitor, on mini-mental state examination (MMSE) score and serum BDNF level in VaD patients. Fifty VaD patients were randomly allocated to receive fluoxetine (20 mg/d; n = 25) or no fluoxetine (control g...
Source: Current Neurovascular Research - August 19, 2013 Category: Neurology Authors: Liu X, Zhang J, Sun D, Fan Y, Zhou H, Fu B Tags: Curr Neurovasc Res Source Type: research

Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report
Conclusion Given emerging evidence that mitochondrial dysfunction, particularly in the electron transport chain needed for cellular energy production, is an underlying pathophysiological mechanism for some varieties of ASD, clinicians should have a high index of suspicion for mitochondrial disease, especially when they encounter a patient with unusual neurological or constitutional symptoms. The prevalence of mitochondrial disease in ASD patients may be as high as five percent, which means that it is not the “zebra”[27] diagnosis that it might be in a non-ASD patient, where prevalence is about 0.01 percent.10 Reference...
Source: Innovations in Clinical Neuroscience - October 9, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Anxiety Disorders Asperger's syndrome Autism Behavioral and Cognitive Neurology Case Report Current Issue Intellectual Disability Neurologic Systems and Symptoms Pervasive Developmental Disorders ASD autism spectrum disorder dysauton Source Type: research

Potassium 2-(1-hydroxypentyl)-benzoate improves depressive-like behaviors in rat model
In this study, we demonstrated that PHPB improved depressive-like behaviors induced by chronic unpredictable mild stress (CUMS) in rats. Male SD rats were subjected to the stress for five weeks. PHPB (30 and 100 mg/kg) or fluoxetine (FLX 10 mg/kg, as positive control) was administered orally from the third week in CUMS procedure. The behavioral tests were applied and then the biochemical studies were carried out. PHPB or FLX treatment rescued the behavioral deficiency in CUMS-exposed rats. Meanwhile, PHPB normalized the enhanced level of serum corticosterone, improved hippocampal and serum BDNF levels, as well as...
Source: Acta Pharmaceutica Sinica B - August 21, 2018 Category: Cancer & Oncology Source Type: research

Effect of fluoxetine on HIF-1 α- Netrin/VEGF cascade, angiogenesis and neuroprotection in a rat model of transient middle cerebral artery occlusion.
Effect of fluoxetine on HIF-1α- Netrin/VEGF cascade, angiogenesis and neuroprotection in a rat model of transient middle cerebral artery occlusion. Exp Neurol. 2020 Apr 12;:113312 Authors: Hu Q, Liu L, Zhou L, Lu H, Wang J, Chen X, Wang Q Abstract Fluoxetine is one of the most promising drugs for improving clinical outcome in patients with ischemic stroke. This in vivo study investigated the hypothesis that fluoxetine may affect HIF-1α-Netrin/VEGF cascade, angiogenesis and neuroprotection using a rat model of transient middle cerebral artery occlusion (tMCAO). The rats were given fluoxetine or salin...
Source: Experimental Neurology - April 11, 2020 Category: Neurology Authors: Hu Q, Liu L, Zhou L, Lu H, Wang J, Chen X, Wang Q Tags: Exp Neurol Source Type: research

Pathological Laughing: Brain SPECT Findings
We present the case of a 40-year-old man consulting for uncontrollable episodes of laughing related to emotional lability and not systematically linked to feelings of happiness. Seven months earlier he had presented a pontine ischemic stroke related to an occlusion of the basilar and left vertebral arteries. No epileptic activity or new MRI brain lesions were found. Brain perfusion SPECT performed showed marked hypoperfusion in the right frontal inferior and temporoinsular regions, suggesting a diaschisis phenomenon caused by pontine lesions and highlighted laughing regulation pathways. The patient was successfully treated...
Source: Clinical Nuclear Medicine - August 11, 2015 Category: Nuclear Medicine Tags: Interesting Images Source Type: research

Comparison between herbal medicine and fluoxetine for depression: A systematic review of randomized controlled trials.
CONCLUSIONS: Due to the poor quality of included trials and the potential publication bias of this review, no confirmed conclusion could be draw to evaluate the effectiveness and safety of CHM for depression compared with fluoxetine. PMID: 26365447 [PubMed - in process]
Source: Complementary Therapies in Medicine - September 16, 2015 Category: Complementary Medicine Authors: Ren Y, Zhu C, Wu J, Zheng R, Cao H Tags: Complement Ther Med Source Type: research

The ms-smart trial in secondary progressive multiple sclerosis: a multi-arm, multi-centre trial of neuroprotection
There is currently no treatment for secondary progressive multiple sclerosis (SPMS) which determines the majority of disability in multiple sclerosis. The MS-SMART trial is a multi-arm, multi-centre, phase 2 randomised trial for patients with SPMS. A total of 440 patients with progressing SPMS will be recruited in England and Scotland and randomised to one of 4 blinded arms: amiloride 5mg bd, riluzole 50mg bd, fluoxetine 20mg bd or placebo. These agents have been chosen after an extensive systematic review which has suggested putative neuroprotective properties. Patients will be followed up for 96 weeks with outcome data c...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Giovannoni, G., Wheeler-Kingshott, C., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., for the MS-SMART trialists Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) Thur 21, Parallel session 5: Therapeutics Source Type: research

Should This Patient With Ischemic Stroke Receive Fluoxetine?
Publication date: December 2015 Source:PM&R, Volume 7, Issue 12 Author(s): Heidi Schambra, Brian Im, Michael W. O'Dell
Source: PMandR - December 18, 2015 Category: Rehabilitation Source Type: research

Modulatory effect of cilostazol on tramadol-induced behavioral and neurochemical alterations in rats challenged across the forced swim despair test
Publication date: Available online 30 May 2016 Source:Beni-Suef University Journal of Basic and Applied Sciences Author(s): Noha M. Gamil, Yousreya A. Maklad, Maha A.E. Ahmed, Shahira Nofal, Amany A.E. Ahmed Pain-associated depression is encountered clinically in some cases such as cancer, chronic neuropathy, and after operations. Tramadol is an opioid analgesic drug that may modulate monoaminergic neurotransmission by inhibition of noradrenaline and serotonin reuptake that may contribute to its antidepressant-like effects. Clinically, tramadol is used either alone or in combination with other NSAIDs in the treatmen...
Source: Beni Suef University Journal of Basic and Applied Sciences - May 30, 2016 Category: Science Source Type: research

The ms-smart trial in secondary progressive ms - current update
MS-SMART is an ongoing multicentre, multi-arm, double blind, placebo-controlled phase IIb randomised controlled trial to establish whether putative neuroprotective drugs (fluoxetine,riluzole,amiloride or placebo) can slow down the progression of brain volume loss in secondary progressive multiple sclerosis (SPMS) over 96 weeks using MRI-derived Percentage Brain Volume Change (PBVC) as the primary outcome. 360 patients have been screened so far, 328 (92%) consented and 272 randomized (65% of the total UK cohort–440). Patients will have outcome-data collected after 0,24,48 and 96 weeks. The trial is using a range of co...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Connick, P., Giovannoni, G., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., Plantone, D. Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

The risk of initiating fluoxetine for motor deficits after ischemic stroke in patients with bipolar disorder
Discussion Ayahuasca administration in controlled settings appear to be safe. Moreover, ayahuasca seem to have therapeutic effects for treatment-resistant psychiatric disorders that should be further investigated in randomized controlled clinical trials. However, medical complications and cases of prolonged psychotic reactions have been reported, and people with personal or family history of psychotic disorders should avoid ayahuasca intake.
Source: Revista de Psiquiatria Clinica - August 31, 2017 Category: Psychiatry Source Type: research

Gastrointestinal Hemorrhage Related to Fluoxetine in a Patient With Stroke
We report on a patient who developed massive gastrointestinal hemorrhage related to the use of fluoxetine in combination with aspirin and clopidogrel. A 58-year-old man was admitted with a posterior circulation infarct with significant weakness in all four limbs and dysarthria. Aspirin and clopidogrel were started. Fluoxetine was started for pharmacological neurostimulation to promote motor recovery and for low mood. He developed gastrointestinal hemorrhage a week after fluoxetine was started. Fluoxetine was suspended and investigations failed to reveal the source of the bleeding. He was then restarted on fluoxetine along ...
Source: American Journal of Physical Medicine and Rehabilitation - October 23, 2017 Category: Rehabilitation Tags: Case Reports Source Type: research

Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study
To investigate whether fluoxetine improves poststroke dysphagia and to detect the potential relationship between serum brain-derived neurotrophic factor (BDNF) levels and fluoxetine effects.
Source: Journal of Stroke and Cerebrovascular Diseases - August 30, 2018 Category: Neurology Authors: Jianting Huang, Xuanwei Liu, Xun Luo, Chunzhi Tang, Mingzhu Xu, Lisa Wood, Yulong Wang, Qing Mei Wang Source Type: research

Fluoxetine and recovery after stroke
Publication date: Available online 5 December 2018Source: The LancetAuthor(s): H Bart van der Worp
Source: The Lancet - December 5, 2018 Category: General Medicine Source Type: research

Fluoxetine and its metabolite norfluoxetine induce microglial apoptosis
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - January 5, 2019 Category: Neuroscience Authors: Kamaldeep S. Dhami, Matthew A. Churchward, Glen. B. Baker, Kathryn G. Todd Tags: Original Article Source Type: research